Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
31-45 of 4028 results
Daiichi Sankyo, ArQule’s tivantinib fails to meet primary end point in liver cancer study
By PBR Staff Writer
Daiichi Sankyo and ArQule announced that the tivantinib has failed to meet its primary endpoint in a phase 3 liver cancer study.
Contract Research & Services > Clinical Trials > News
AstraZeneca's Lynparza meets primary endpoint in breast cancer study
By PBR Staff Writer
A phase 3 study of AstraZeneca’s Lynparza (olaparib) met primary endpoint in a phase III trial in BRCA-mutated metastatic breast cancer.
Contract Research & Services > Clinical Trials > News
Pfizer's Xeljanz goes head-to-head with AbbVie's Humira in RA study
By PBR Staff Writer
Pfizer said its rheumatoid arthritis drug, Xeljanz, met primary endpoint in combination with methotrexate as compared to AbbVie's drug Humira, although it did not meet the primary endpoint on its own.
Contract Research & Services > Clinical Trials > News
Ardelyx's tenapanor shows significant effect in hyperphosphatemia in phase 3 trial
By PBR Staff Writer
A phase 3 trial evaluating Ardelyx's tenapanor, a novel treatment for hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis, met its primary endpoint of significant difference in serum phosphorus levels.
Contract Research & Services > Clinical Trials > News
ViiV Healthcare unveils positive study results for two-drug regimen for HIV
ViiV Healthcare has announced positive results from its phase 3 program assessing the safety and efficacy of switching virologically suppressed patients from a three- or four-drug antiretroviral regimen to a two-drug regimen of dolutegravir and rilpivirine.
Contract Research & Services > Clinical Trials > News
Merck halts clinical trial of Alzheimer's drug
By PBR Staff Writer
Merck said it will halt a phase 2/3 clinical study of an experimental Alzheimer’s drug due to lack of efficacy.
Contract Research & Services > Clinical Trials > News
Axovant's nelotanserin demonstrates treatment benefit in phase 2 dementia study
By PBR Staff Writer
Axovant Sciences said its drug nelotanserin has passed an early hurdle in a phase 2 study for Lewy body dementia, encouraging it to start preparing for a phase 3 study.
Contract Research & Services > Clinical Trials > News
Tracon's lead product candidate fails in phase 2 study in brain cancer trial
Tracon Pharmaceuticals said that data from a phase 2 study demonstrated that a combination of its endoglin antibody TRC105 with Avastin (bevacizumab) did not perform significantly better than Avastin alone for progression-free survival in patients with recurrent glioblastoma.
Contract Research & Services > Clinical Trials > News
Immunomedics, Seattle Genetics sign $2bn licensing deal for cancer drug
By PBR Staff Writer
Immunomedics has signed a development and licensing agreement worth up to $2bn with Seattle Genetics for its experimental cancer drug.
Contract Research & Services > Clinical Trials > News
Jazz enrolls first patient in JZP-110’s phase 2 trial for excessive sleepiness in PD patients
Jazz Pharmaceuticals has enrolled its first patient for the Phase 2 clinical study of JZP-110, a selective dopamine and norepinephrine reuptake inhibitor, as a potential option for excessive sleepiness (ES) in adult patients with Parkinson's disease.
Contract Research & Services > Clinical Trials > News
Viking's VK2809 demonstrates positive effect in POC study in glycogen storage disease
Preliminary results from a proof-of-concept (POC) study evaluating Viking Therapeutics' VK2809 in an in vivo model of a rare orphan disorder, dubbed glycogen storage disease Ia (GSD 1a), demonstrated an encouraging effect.
Contract Research & Services > Clinical Trials > News
Male contraceptive gel succeds in monkey trials
By PBR Staff Writer
A new type of male contraceptive polymer hydrogel which works by blocking sperm in the vas deferens has been successful in monkey trials.
Contract Research & Services > Clinical Trials > News
GW Pharmaceuticals' Cannabis-derived drug shows promise in brain cancer trial
GW Pharmaceuticals has unveiled positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in 21 patients with recurrent glioblastoma multiforme, or GBM.
Contract Research & Services > Clinical Trials > News
Immunovaccine’s immuno-oncology candidate to enter phase 2 trial in ovarian cancer
Immunovaccine has announced that the UHN’s Princess Margaret Cancer Centre (PM) will carry out a Phase 2 clinical trial to assess the use of a combination of immunotherapies from Immunovaccine and Merck.
Contract Research & Services > Clinical Trials > News
Ergomed’s insomnia drug meets primary endpoint in phase 2 trial
By PBR Staff Writer
A phase 2 clinical study evaluating Ergomed's Lorediplon met the primary endpoint with high statistical significance, indicating the drug has strong efficacy in sleep maintainance.
Contract Research & Services > Clinical Trials > News
31-45 of 4028 results